Month: February 2023

Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone was written by Taurines, R.;Fekete, S.;Preuss-Wiedenhoff, A.;Warnke, A.;Wewetzer, C.;Plener, P.;Burger, R.;Gerlach, M.;Romanos, M.;Egberts, K. M.. And the article was included in Journal of Neural Transmission in 2022.Recommanded Product: 144598-75-4 This article mentions the following:

Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose-concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20-60 ng/mL) is applicable for minors. In the 64 patients (aged 11-18 years) included, a pos. correlation between daily dose and the active moiety (RIS_am) concentration was found (r_s = 0.49, p = 0.001) with variation in dose explaining 24% (r_s² = 0.240) of the variability in serum concentrations While the RIS_am concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RISam concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS_am was determined to be 33 ng/mL. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Recommanded Product: 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The electrophilic cyclization of various 2-alkynone O-methyl oximes with a wide range of substrates such as ICl, I2, Br2, PhSeBr, etc. provides a variety of 3,4,5-trisubstituted isoxazoles in good to excellent yields.Recommanded Product: 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

ACE2:S1 RBD interaction-targeted peptides and small molecules as potential COVID-19 therapeutics was written by Chitsike, Lennox;Krstenansky, John;Duerksen-Hughes, Penelope J.. And the article was included in Advances in Pharmacological and Pharmaceutical Sciences in 2021.Reference of 883944-52-3 This article mentions the following:

The COVID-19 pandemic that began in late 2019 continues with new challenges arising due to antigenic drift as well as individuals who cannot or choose not to take the vaccine. There is therefore an urgent need for addnl. therapies that complement vaccines and approved therapies such as antibodies in the fight to end or slow down the pandemic. SARS-CoV-2 initiates invasion of the human target cell through direct contact between the receptor-binding domain of its Spike protein and its cellular receptor, angiotensin-converting enzyme-2 (ACE2). The ACE2 and S1 RBD interaction, therefore, represents an attractive therapeutic intervention to prevent viral entry and spread. In this study, we developed a proximity-based AlphaScreen assay that can be utilized to quickly and efficiently screen for inhibitors that perturb the ACE2:S1 RBD interaction. We then designed several peptides candidates from motifs in ACE2 and S1 RBD that play critical roles in the interaction, with and without modifications to the native sequences. We also assessed the possibility of reprofiling of candidate small mols. that previously have been shown to interfere with the viral entry of SARS-CoV. Using our optimized AlphaScreen assay, we evaluated the activity and specificity of these peptides and small mols. in inhibiting the binding of ACE2:S1 RBD. This screen identified cepharanthine as a promising candidate for development as a SARS-CoV-2 entry inhibitor. In the experiment, the researchers used many compounds, for example, N-(4-(4-Methylpiperazin-1-yl)benzyl)isoxazole-5-carboxamide (cas: 883944-52-3Reference of 883944-52-3).

N-(4-(4-Methylpiperazin-1-yl)benzyl)isoxazole-5-carboxamide (cas: 883944-52-3) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Reference of 883944-52-3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Phosphate binder for dialysis patients was written by Becker, Conny;Gensthaler, Brigitte M.;Grafe, Kerstin A.;Morck, Hartmut. And the article was included in Pharmazeutische Zeitung in 2007.Application In Synthesis of Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide This article mentions the following:

Characteristics, pharmacodynamics, and pharmacokinetics are discussed of a new Ca-free phosphate binder, lanthanum carbonate (Fosrenol), for dialysis patients with terminal nephrotic insufficiency to avoid hyperphosphatemia. 4 New drugs are characterized: oxytocin analog carbetocin (Pabal), Tyr kinase inhibitor dasatinib (Sprycel), cyclooxygenase (COX)-2 inhibitor lumiracoxib (Prexige), and endothelin-A-receptor inhibitor sitaxentan (Thelin). In the experiment, the researchers used many compounds, for example, Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2Application In Synthesis of Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide).

Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application In Synthesis of Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants was written by Altman, Michael D.;Ali, Akbar;Reddy, G. S. Kiran Kumar;Nalam, Madhavi N. L.;Anjum, Saima Ghafoor;Cao, Hong;Chellappan, Sripriya;Kairys, Visvaldas;Fernandes, Miguel X.;Gilson, Michael K.;Schiffer, Celia A.;Rana, Tariq M.;Tidor, Bruce. And the article was included in Journal of the American Chemical Society in 2008.HPLC of Formula: 321309-26-6 This article mentions the following:

The acquisition of drug-resistant mutations by infectious pathogens remains a pressing health concern, and the development of strategies to combat this threat is a priority. Here the authors have applied a general strategy, inverse design using the substrate envelope, to develop inhibitors of HIV-1 protease. Structure-based computation was used to design inhibitors predicted to stay within a consensus substrate volume in the binding site. Two rounds of design, synthesis, exptl. testing, and structural anal. were carried out, resulting in a total of 51 compounds Improvements in design methodol. led to a roughly 1000-fold affinity enhancement to a wild-type protease for the best binders, from a K_i of 30-50 nM in round one to below 100 pM in round two. Crystal structures of a subset of complexes revealed a binding mode similar to each design that respected the substrate envelope in nearly all cases. All four best binders from round one exhibited broad specificity against a clin. relevant panel of drug-resistant HIV-1 protease variants, losing no more than 6-13-fold affinity relative to wild type. Testing a subset of second-round compounds against the panel of resistant variants revealed three classes of inhibitors: robust binders (maximum affinity loss of 14-16-fold), moderate binders (35-80-fold), and susceptible binders (greater than 100-fold). Although for especially high-affinity inhibitors addnl. factors may also be important, overall, these results suggest that designing inhibitors using the substrate envelope may be a useful strategy in the development of therapeutics with low susceptibility to resistance. In the experiment, the researchers used many compounds, for example, 5-Methyl-4-isoxazolesulfonyl chloride (cas: 321309-26-6HPLC of Formula: 321309-26-6).

5-Methyl-4-isoxazolesulfonyl chloride (cas: 321309-26-6) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.HPLC of Formula: 321309-26-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Some dimethyldiisoxazolone derivatives was written by Caramella, Pierluigi;Gruenanger, Paolo. And the article was included in Chimica e l’Industria (Milan, Italy) in 1967.Related Products of 19668-85-0 This article mentions the following:

3-Methyl-4-(3-methylisoxazol-5-yl)-3-isoxazolin-5-one [I (R = H)] (II) is prepared and used in the preparation of III and IV. II, m. 169-70° (decomposition), is prepared according to 3 known methods. A solution is prepared from 9.0 g. II and 38 ml. POCl3, 7.0 ml. Et3N is slowly added, and the mixture is refluxed 90 min. to give 64% III (X = Cl) (V), m. 89-90° (hexane). A mixture of 1.0 g. V in C6H6 is treated with 3.0 ml. morpholine and the mixture is kept 2 days to give 96% III (X = morpholino), m. 89-90° (cyclohexane); N.M.R. data are given. A solution of 1.0 g. V in 30 ml. 0.24M KOH (MeOH) is agitated 3 hrs. to give 72% III (X = MeO) (VI), m. 73-4° (ligroine). Similarly prepared is III (X = EtO), m. 89-90° (hexane). VI (0.5 g.) in 50 ml. MeOH is hydrogenated in the presence of 0.1 g. 5% Pd/C to give 90% Me 2-(3-methylisoxazol-5-yl)-3-aminocrotonate (VII), m. 91-2° (C6H6-hexane). Similarly prepared is IV [R = C(CO2Et):C(NH2)Me] (VIII), m. 106-7° (C6H6-hexane); acetyl derivative m. 84-5° (cyclohexane). A mixture of 2.55 millimoles VII (or VIII) and 15 ml. 1:1 H2SO4 is refluxed 1 hr. to give IV (R = CH2CO2H), m. 106-7° (C6H6). A solution of 120 mg. VII and 50 mg. HONH2.HCl in 20 ml. EtOH is refluxed 2 hrs. to give 82% II, m. 167-8° (decomposition) (water). A solution of 0.5 g. VII and 0.22 g. HONHMe.HCl in 20 ml. EtOH is refluxed 2 hrs. to give 71% I (R = Me) (VIII), m. 163-4° (water). II (10 millimoles) is treated with excess CH2N2 to give a mixture of VI and VIII. Similarly prepared is a mixture of III (X = EtO) (IX) and I (R = Et) (X), m. 97-8° (iso-Pr2O). A mixture of 4.5 millimoles II in 10 ml. water is neutralized with 0.5N NaOH, 0.1N AgNO3 is added, and the mixture is heated with MeI in C6H6 to give a mixture of VI and VIII. Similarly prepared is a mixture of IX and X. Ir and uv data are given. In the experiment, the researchers used many compounds, for example, 3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0Related Products of 19668-85-0).

3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Related Products of 19668-85-0

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Regio- and stereoselective synthesis of 2-alkylidene-hydrofurans by domino-cyclodialkylations of 1,3-dicarbonyl-dianions with 1-bromo-2-chloroethane was written by Langer, Peter;Karime, Inass. And the article was included in Synlett in 2000.SDS of cas: 5765-44-6 This article mentions the following:

Reaction of 1,3-dicarbonyl dianions with 1-bromo-2-chloroethane results in regio- and stereoselective formation of 2-alkylidene-hydrofurans, e.g. I. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6SDS of cas: 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.SDS of cas: 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The coordination chemistry of (py)₂BF⁺₂ and related difluoroboron cations was written by Stephen Hartman, J.;Shoemaker, James A. W.;Janzen, Alex F.;Ragogna, Paul J.;Szerminski, W. R.. And the article was included in Journal of Fluorine Chemistry in 2003.Quality Control of 5-Methylisoxazole This article mentions the following:

The substitution and decomposition reactions of the difluorobis(pyridine)boron(III) cation, and of several substituted pyridine and other difluoroboron cations (D)₂BF₂⁺, are explored. Donor mol. displacement is greatly accelerated by the presence of electron-withdrawing meta and para pyridine substituents in (substituted pyridine)₂BF₂⁺ cations, and by electron-donating substituents on pyridine when the substituted pyridine is the attacking species. Increased steric hindrance of D in D₂BF₂⁺, and of the attacking base D’, slows or prevents displacement of D by D’. [(Py)₂BF₂][PF₆] (py = pyridine) undergoes slow decomposition in acetone, giving initially py·BF₃ and finally [py·H][BF₄] as the major fluoroboron species. A 2nd decomposition pathway, giving rise to BF₃OH^– and several addnl. F-containing products, is favored by the presence of strong bases such as amidines and by the presence of N-H and O-H bonds. Increased susceptibility to ligand displacement facilitates the synthesis of new fluoroboron cations, but also increases the susceptibility to decomposition In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Quality Control of 5-Methylisoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Quality Control of 5-Methylisoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials was written by Gul, Seref;Ozcan, Onur;Asar, Sinan;Okyar, Alper;Baris, Ibrahim;Kavakli, Ibrahim Halil. And the article was included in Journal of Biomolecular Structure and Dynamics in 2021.Name: 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Despite strict measures taken by many countries, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be an issue of global concern. Currently, there are no clin. proven pharmacotherapies for coronavirus disease 2019, despite promising initial results obtained from drugs such as azithromycin and hydroxychloroquine. Therefore, the repurposing of clin. approved drugs for use against SARS-CoV-2 has become a viable strategy. Here, we searched for drugs that target SARS-CoV-2 3C-like protease (3CL^pro) and viral RNA-dependent RNA polymerase (RdRp) by in silico screening of the U.S. Food and Drug Administration approved drug library. Well-tolerated and widely used drugs were selected for mol. dynamics (MD) simulations to evaluate drug-protein interactions and their persistence under physiol. conditions. Tetracycline, dihydroergotamine, ergotamine, dutasteride, nelfinavir, and paliperidone formed stable interactions with 3CL^pro based on MD simulation results. Similar anal. with RdRp showed that eltrombopag, tipranavir, ergotamine, and conivaptan bound to the enzyme with high binding free energies. Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity. As these drugs are well tolerated, cost-effective, and widely used, our study suggests that they could potentially to be used in clin. trials for the treatment of SARS-CoV-2-infected patients. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Name: 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Name: 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Evaluation of the Impacts of Formulation Parameters on the Pharmacokinetics and Bioequivalence of Risperidone Orodispersible Film: a Physiologically Based Pharmacokinetic Modeling Approach was written by Chen, Fang;Liu, Hongrui;Wang, Bing;Yang, Zhou;Chen, Yusheng;Yang, Liuliu;Jiao, Zheng;Lin, Hai-Shu;Quan, Yingjun;Wang, Hao;Xiang, Xiaoqiang. And the article was included in AAPS PharmSciTech in 2020.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

The purpose of this study was to investigate the impacts of the formulation parameters on the pharmacokinetics and bioequivalence of risperidone orodispersible film (ODF) using physiol. based pharmacokinetic model. The pharmacokinetic profiles of two risperidone ODFs, which exhibit different in vitro dissolution, were examined in Beagle dogs after supralingual administration. Subsequently, a physiol. based pharmacokinetic (PBPK) model was constructed to evaluate the in vivo performance of risperidone ODF. The parameter sensitivity anal. (PSA) was used to access the impacts of formulation parameters on the pharmacokinetics of risperidone. Moreover, the validated PBPK model was applied to predict human pharmacokinetic profiles and examine the bioequivalence of these two ODFs. These two ODFs displayed similar risperidone pharmacokinetic profiles in dogs. The parameter sensitivity anal. indicated that the changes in the solubility, particle size, particle d., and diffusion coefficient did not have obvious influence on the in vivo properties of risperidone ODF. Alternation of the in vitro complete dissolution time in water from 15 to 30 min led to a 30% decrease in Cmax and 20% of increase in Tmax. AUC0-∞ would be decreased if risperidone was not fully released within 1 h. As both ODFs completely released risperidone within 15 min, the difference in the extent of in vivo absorption, intestinal regional absorption location, and plasma concentration-time curves between these two ODFs was almost negligible. Consequently, a bioequivalence was foreseen in humans. The in vitro cumulative dissolution percentage in water at 15 min was found to be the major determinant on the in vivo properties of risperidone ODF. PBPK modeling appears to be an innovative strategy to guide the development of risperidone ODF. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases was written by Brown, Dearg S.;Cumming, John G.;Bethel, Paul;Finlayson, Jonathan;Gerhardt, Stefan;Nash, Ian;Pauptit, Richard A.;Pike, Kurt G.;Reid, Alan;Snelson, Wendy;Swallow, Steve;Thompson, Caroline. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2012.Related Products of 14678-05-8 This article mentions the following:

A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clin. candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703). Optimization was guided by understanding of the binding modes from X-ray crystallog. studies which showed a switch from DFG out’ to DFG in’ as the inhibitor size was reduced to improve overall properties. In the experiment, the researchers used many compounds, for example, Isoxazol-5-amine (cas: 14678-05-8Related Products of 14678-05-8).

Isoxazol-5-amine (cas: 14678-05-8) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Related Products of 14678-05-8

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem